Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 18/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 16/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 16/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514396 | 0.95 | PBRM1 (0.43) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24513970 | 0.95 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24514306 | 0.93 | PBRM1 (0.43) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24514491 | 0.87 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24514594 | 0.87 | SMARCA2 (0.43) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24513946 | 0.86 | PBRM1 (0.43) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24513968 | 0.86 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24513942 | 0.85 | PBRM1 (0.42) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24514278 | 0.85 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4BRD4NR1I2 | |
| SCHEMBL24514279 | 0.85 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4BRD4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |